Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Turcot syndrome × denileukin diftitox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Turcot syndrome 1 Melanoma 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

pembrolizumab 3 Nivolumab 2 sintilimab 1 regorafenib 1 denileukin diftitox 1 Radiation Dose Hypofractionation 1 Ipilimumab 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 E7777 fusion protein 1 Clinical Trials, Phase II as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05200559 2024-12-05

T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Recruiting

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡